<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671968</url>
  </required_header>
  <id_info>
    <org_study_id>IDT-1510-SI / HypoDE</org_study_id>
    <nct_id>NCT02671968</nct_id>
  </id_info>
  <brief_title>Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)</brief_title>
  <official_title>Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Science Consulting in Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DexCom, Inc. a Delaware corporation, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Science Consulting in Diabetes</source>
  <brief_summary>
    <textblock>
      Demonstrate that usage of RT-CGM (Real time continuous glucose monitoring) reduces the
      frequency of low CGM-recorded glucose events in patients using MDI (Multiple daily
      injections) that are at risk for hypoglycemic events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a randomized controlled trial the primary hypothesis is tested if the usage of RT-CGM in
      the intervention group (CGM group) reduces the frequency of glucose values &lt;55 mg/dl in
      patients with hypoglycemia problems (hypoglycemia unawareness or documented previous severe
      hypoglycemia) significantly more than in the control group receiving usual care (without
      CGM).

      Secondary is tested if patients in the CGM group showed a significantly more favorable change
      in the below defined secondary endpoint than patients in the control group after 26 weeks
      follow up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">October 24, 2017</completion_date>
  <primary_completion_date type="Actual">July 14, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the total number of low glucose events (&lt;55 mg/dl), between baseline and outcome phase (week 22-26) in CGM group and control group (change = subtracting number of follow up events from number of baseline events</measure>
    <time_frame>For each subject, the experimental phase has an expected duration of up to 7 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>CGM group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring System</intervention_name>
    <arm_group_label>CGM group</arm_group_label>
    <other_name>Dexcom G5 Mobile, Dexcom G4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 1 diabetes for at least 12 months on multiple daily injections
             (MDI). MDI is defined as prandial insulin injections at each major meal (excludes
             pre-mixed insulin) with doses determined by SMBG and carbohydrate counting, and basal
             insulin injection(s)

          -  Age ≥ 18 years

          -  HbA1c ≤ 9.0 % performed within 4 months before begin of the study

          -  High risk for severe hypoglycemia (defined as a score of 4 or higher on the
             Hypoglycemia unawareness scale (HUS) or a history of at least one severe hypoglycemic
             event in the last 12 months (required third part assistance, not able to treat
             themselves))

          -  Willing to not use paracetamol or drugs containing it

          -  Signed and dated Informed Consent Form

        Exclusion Criteria:

          -  Use of personal real-time-CGM 3 months prior to study entry and during the study
             (except study devices)

          -  Use of a flash-glucose monitoring system 3 months prior to study and during the study

          -  Alcoholism or drug abuse

          -  Unable to comply with the protocol at the investigators discretion, such as known
             psychiatric diagnosis, cognitive / physical decline

          -  Pregnancy or lactation period

          -  Severe known allergies, e.g. against plaster

          -  Mental incapacity or language barriers precluding adequate compliance with the study
             procedures

          -  Limited or no legal capacity or legal guardianship

          -  Dependency from the sponsor or the clinical investigator (e.g. co-workers of the
             sponsor or the clinical research center or their families)

          -  Participation in another study at the same time with a non-approved drug or a
             non-CE-labelled medical device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Hermanns, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Forschungsinstitut Diabetes-Akademie Bad Mergentheim (FIDAM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Klausmann</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>m&amp;i-Fachklinik Bad Heilbrunn</name>
      <address>
        <city>Bad Heilbrunn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forschungsinstitut Diabetes-Akademie Bad Mergentheim (FIDAM)</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis</name>
      <address>
        <city>Bergheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicover Berlin-Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologikum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Praxis Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis mit Fußambulanz</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Diabetologie Bergedorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Kaltheuner</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Schwerpunkt Praxis Zentrum für Hormone und Stoffwechsel</name>
      <address>
        <city>Marktredwitz</city>
        <zip>95615</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Diabetes und Ernährungsmedizin</name>
      <address>
        <city>Münster</city>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/29459019</url>
    <description>Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CGM</keyword>
  <keyword>hypoglycemic events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

